Juan C. Jaen - Jun 15, 2023 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
President, Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Stock symbol
RCUS
Transactions as of
Jun 15, 2023
Transactions value $
-$93,267
Form type
4
Date filed
6/16/2023, 08:14 PM
Previous filing
Jan 25, 2023
Next filing
Dec 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Gift $0 -6K -1.85% $0.00 319K Jun 15, 2023 Direct F1
transaction RCUS Common Stock Disposed to Issuer -$93.3K -4.82K -1.51% $19.35 314K Jun 16, 2023 Direct F2, F3
holding RCUS Common Stock 1.22M Jun 15, 2023 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a gift to a family trust over which the reporting person has neither voting nor investment control.
F2 Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.86 to $19.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.